



Psa-V Product Testing – Field Trial Report

Trial 3 - Supplement

**Leaf spotting on regrowth from Hort16A
(on Bruno) potted plants previously treated with
Actigard and KeyStrepto**

December 2011 - March 2012



26 April 2012

Disclaimer

This report has been prepared based on information available at the time of publication which is inherently preliminary in nature and subject to change. No party, including without limitation, Kiwifruit Vine Health Incorporated, Plant & Food Research and ZESPRI Group Limited, makes any warranty, representation or guarantee as to the accuracy and/or completeness of the information regarding Psa, potential treatments and/or best treatment practice, and none of those parties shall be liable to any person for any loss arising from that person's reliance on the information and/or for any damages arising out of or connected with the use of the enclosed information. No obligation is accepted or undertaken to update this or any other information or publicly release revisions to this document to reflect additional information, circumstances or changes in expectations which occur after the date of this document.



Summary

This report supplements the report for Trial 3 in which various protectants were applied to Hort16A plants (in December/January 2012). Here, the amounts of leaf spotting observed on re-growth from plants previously sprayed with Actigard and KeyStrepto is presented.

In trial 3, plants were treated in the first week of December 2011 then assessed for leaf spotting for about a month. In mid-January the tops of the plants treated with Actigard, KeyStrepto and water (prior to active inoculation with Psa-V) were cut off above the graft then allowed to re-grow. Leaf spotting on the subsequent re-growth originating from both the Bruno rootstock and Hort16A scion was assessed in early March approximately 3 months after the plants were treated.

No differences were observed in the amount of leaf spotting on re-growths approximately three months after treatment (Figure 1). It is therefore concluded that under the conditions of this trial any systemic protection offered by Actigard or KeyStrepto was short-lived and less than three months.

Figure 1. Average amounts of leaf spotting on re-growths from Hort16A (on Bruno) potted plants previously treated with Actigard and KeyStrepto (n = 20 per treatment). None of the values are significantly different from each other (according to a Wilcoxon test).

